当前位置: 首页 >> 检索结果
81. Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial.
作者: James Goadsby.;Argyro Syngelaki.;Laura A Magee.;Peter von Dadelszen.;Ranjit Akolekar.;Sophie Webster.;Alan Wright.;David Wright.;Kypros H Nicolaides.
来源: Lancet. 2026年407卷10523期67-77页
In high-risk pregnancies, there is no reliable intervention to reduce term pre-eclampsia. We aimed to investigate the effect of screening for pre-eclampsia risk at 36 weeks' gestation and offering risk-stratified, planned, early-term birth.
82. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
作者: Emma Guttman-Yassky.;Kenji Kabashima.;Margitta Worm.;Paula C Luna.;H Chih-Ho Hong.;Raj Chovatiya.;Jonathan A Bernstein.;Johannes S Kern.;Benjamin D Ehst.;Nina Magnolo.;Pedro Herranz-Pinto.;Linda Stein Gold.;Howard Sofen.;Andrew E Pink.;Ehsanollah Esfandiari.;Takahiro Arai.;Yiping Yang.;Rebecca Shi.;Carolina Barragan.;Greg Kricorian.;Liat Schwartz-Sagi.;Robert Bissonnette.
来源: Lancet. 2026年407卷10523期53-66页
Rocatinlimab is a T cell rebalancing therapy that inhibits and reduces the number of pathogenic T cells by targeting the OX40 receptor expressed on the surface of activated T cells. Two global phase 3 studies were performed to assess the efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in adults.
83. Efficacy and safety of nipocalimab in patients with moderate-to-severe Sjögren's disease (DAHLIAS): a randomised, phase 2, placebo-controlled, double-blind trial.
作者: Ghaith Noaiseh.;Kathy L Sivils.;Kim Campbell.;Jada Idokogi.;Kim Hung Lo.;Sophia G Liva.;Jocelyn H Leu.;Harman Dhatt.;Keying Ma.;Steven Leonardo.;He Li.;Jonathan J Hubbard.;Jacques-Eric Gottenberg.
来源: Lancet. 2025年406卷10518期2435-2448页
Sjögren's disease is characterised by mucosal dryness, fatigue, chronic pain, systemic organ involvement, and elevated autoreactive IgG antibodies. There are no approved disease-modifying treatments. Therefore, we aimed to evaluate nipocalimab, a neonatal Fc receptor blocker that reduces circulating IgG, including autoantibodies, in patients with Sjögren's disease.
84. Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 × 2 factorial phase 3 trial.
作者: Michele Reni.;Marina Macchini.;Giulia Orsi.;Letizia Procaccio.;Giuseppe Malleo.;Catia Carconi.;Ilario Giovanni Rapposelli.;Katia Bencardino.;Mario Scartozzi.;Gianpaolo Balzano.;Domenico Tamburrino.;Barbara Merelli.;Elisa Sperti.;Giulio Belfiori.;Nicole Liscia.;Silvia Bozzarelli.;Mariacristina Di Marco.;Emiliano Tamburini.;Michele Milella.;Sara Lonardi.;Giorgio Ercolani.;Michele Mazzola.;Diego Palumbo.;Valter Torri.;Massimo Falconi.
来源: Lancet. 2026年406卷10522期2945-2956页
Perioperative chemotherapy is a standard option for treatment of patients with resectable and borderline resectable pancreatic ductal adenocarcinoma (PDAC). This study aimed to assess the superiority of PAXG (cisplatin, nab-paclitaxel, capecitabine, and gemcitabine) over mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, and oxaliplatin) in this population.
85. Comparison of inhalational methoxyflurane, intranasal fentanyl, and intravenous morphine for treatment of prehospital acute pain in Norway (PreMeFen): a randomised, non-inferiority, three-arm, phase 3 trial.
作者: Randi Simensen.;Lars Olav Fjose.;Kjetil Thorsen.;Inge Christoffer Olsen.;Marius Rehn.;Jostein Hagemo.;Live Smalberget.;Fridtjof Heyerdahl.
来源: Lancet. 2026年406卷10522期2957-2967页
Adequate pain control is essential; however, acute pain is often undertreated in prehospital care. This study aimed to evaluate three analgesic regimens for treating acute pain in an ambulance setting.
86. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
作者: Deborah B Horn.;Donna H Ryan.;Sanja Giljanovic Kis.;Breno Alves.;Yiming Mu.;Sin Gon Kim.;Jens Aberle.;Stephen C Bain.;Sheryl Allen.;Elizabeth Sarker.;Qiwei Wu.;Adam Stefanski.;Irina Jouravskaya.; .
来源: Lancet. 2026年406卷10522期2927-2944页
Obesity is a chronic disease that significantly contributes to type 2 diabetes and its complications. We aimed to evaluate orforglipron, an oral small-molecule (non-peptide) GLP-1 receptor agonist, for obesity treatment in adults with type 2 diabetes.
87. Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study.
作者: Robert W Frenck.;Abdi Naficy.;Jodi Feser.;Michelle P Dickey.;Victor H Leyva-Grado.;Michael A Egan.;Tracy Chen.;John H Eldridge.;Susan Sciotto-Brown.;Luz Hermida.;Dominique Promeneur.;Amara Luckay.;Herbert Medina.;Glorie-Grace A Lazaro.;Nairuti R Patel.;Tahira Naqvi.;Christopher C Broder.;Antony S Dimitrov.;Chris Gast.;Laina D Mercer.;Mike Raine.;Indah Andi-Lolo.;Bruce L Innis.;John J Aponte.;Stefan Hamm.;Niraj Rathi.
来源: Lancet. 2025年406卷10521期2792-2803页
First discovered in 1999 in Malaysia, Nipah virus (NiV) causes yearly outbreaks throughout south and southeast Asia with associated mortality rates of 40-75%. Due to the structural and sequence similarities between the NiV and Hendra virus (HeV) attachment G glycoproteins, and the extensive extant evidence of the ability of a recombinant soluble glycoprotein G (HeV-sG) to provide heterologous cross-protective immunity when used as vaccine (HeV-sG-V), this study aimed to evaluate HeV-sG-V for safety, tolerability, and immunogenicity against NiV.
88. A preventive care strategy to reduce moderate or severe acute kidney injury after major surgery (BigpAK-2); a multinational, randomised clinical trial.
作者: Alexander Zarbock.;Marlies Ostermann.;Lui Forni.;Christian Bode.;Lennart Wild.;Christian Putensen.;Diego Parise Roux.;Elena Elías Martín.;Christian Arndt.;Tim Rahmel.;Silvia de Rosa.;Céline Monard.;Antoine G Schneider.;Adam Glass.;Mona Jung-König.;Stefano Romagnoli.;James Gossage.;Nuttha Lumlertgul.;Jan Gerrit Haaker.;Javier Ripollés-Melchor.;Savino Spadaro.;Antonio Siniscalchi.;Emmanuel Futier.;Lucie Aupetitgendre.;Irene Romero Bhathal.;Raquel García Álvarez.;Alice Bernard.;Peter Rosenberger.;Carola Wempe.;Mahan Sadjadi.;Melanie Meersch.;Karen Fischhuber.;Rinaldo Bellomo.;John A Kellum.;Thilo von Groote.; .
来源: Lancet. 2025年406卷10521期2782-2791页
Acute kidney injury (AKI) is a common and important complication of major surgery, yet recommended preventive care is rarely administered. We used urinary biomarkers to identify patients at high risk of AKI and implemented a preventive care strategy to reduce AKI within 72 h after major surgery.
89. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
作者: Mazen Noureddin.;Stephen A Harrison.;Rohit Loomba.;Naim Alkhouri.;Naga Chalasani.;Muhammad Y Sheikh.;Shaheen Tomah.;Julio A Gutierrez.;Silvia Urbina.;John J Suschak.;Randy Brown.;Ozioma Odili.;Jay Yang.;Stephine Keeton.;Guy Neff.;Edward Mena.;M Scot Roberts.;Sarah K Browne.;M Scott Harris.
来源: Lancet. 2025年406卷10520期2644-2655页
GLP-1-glucagon dual receptor agonists such as pemvidutide have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of this trial was to assess the effects of pemvidutide on MASH resolution and fibrosis improvement in patients with liver fibrosis stage F2 or F3 MASH at 24 weeks of treatment.
90. Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial.
作者: Anette-Gabriele Ziegler.;Peter Achenbach.;Andreas Weiß.;Reinhard Berner.;Kristina Casteels.;Helena Elding Larsson.;Florian Haupt.;Angela Hommel.;An Jacobs.;Olga Kordonouri.;Markus Lundgren.;Mariusz Ołtarzewski.;Markus Pfirrmann.;Matthew D Snape.;Agnieszka Szypowska.;John A Todd.;Manu Vatish.;Thekla von dem Berge.;Christiane Winkler.;Ezio Bonifacio.; .
来源: Lancet. 2025年406卷10519期2564-2576页
Type 1 diabetes begins with autoimmunity against pancreatic islet antigens, including insulin. The aim of the Primary Oral Insulin Trial (POInT) was to evaluate the efficacy and safety of daily high-dose oral insulin to prevent the development of islet autoantibodies and diabetes.
91. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial.
作者: Hiddo J L Heerspink.;José F Cardona.;Shivinder Jolly.;Pablo E Pergola.;Erika de Sousa-Amorim.;Anna L Eriksson.;Martin Fredholm.;Samvel B Gasparyan.;Nicolas J Guzman.;Judith Hartleib-Geschwindner.;Yunyun Jiang.;Maria Leonsson-Zachrisson.;Patrick B Mark.; .
来源: Lancet. 2025年406卷10518期2449-2460页
Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce albuminuria and risk of progression of chronic kidney disease. Non-steroidal mineralocorticoid receptor antagonists (MRA) have similar effects in patients with type 2 diabetes with chronic kidney disease. We aimed to assess efficacy and safety of the novel MRA balcinrenone combined with the SGLT2 inhibitor dapagliflozin in a randomised controlled trial.
92. Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials.
作者: Jeffrey I Weitz.;Aaron P Kithcart.;Meagan P O'Brien.;Oren Levy.;Ethan Marin.;Margaret Onisko.;Kusha A Mohammadi.;Dateng Li.;Karoline A Meagher.;Hannah H Chang.;Benjamin A Olenchock.;David E Gutstein.;Annelise Segers.;Robin S Roberts.;Marc P Bonaca.;Gary E Raskob.
来源: Lancet. 2025年406卷10519期2551-2563页
Coagulation factor XI (FXI) inhibitors can reduce the incidence of thrombosis without increasing bleeding risk. FXI is activated by factor XIIa (FXIIa) or thrombin. REGN7508Cat is an antibody that binds to the FXI catalytic domain, blocking both its activity and activation by FXIIa and thrombin. REGN9933A2 binds to the FXI apple 2 domain and blocks FXI activation by FXIIa. We aimed to compare the efficacy and safety of REGN9933A2 and enoxaparin, with apixaban as an exploratory comparator, and REGN7508Cat and enoxaparin for venous thromboembolism prevention.
93. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
作者: Liana K Billings.;Stanley Hsia.;Harold Bays.;Beth Tidemann-Miller.;Jessica O'Hagan.;Lai San Tham.;Annabelle Butler.;Christof Kazda.;Kieren J Mather.;Tamer Coskun.
来源: Lancet. 2025年406卷10520期2631-2643页
Amylin-based therapies are emerging as promising obesity medications. Eloralintide is a novel, selective amylin receptor agonist in development for weight management. We performed a phase 2, double blind, randomised, placebo-controlled trial with the aim of evaluating the efficacy and safety of a range of doses and dose escalation schemes of once-per-week eloralintide versus placebo in adults with obesity or overweight and had at least one weight-related comorbidity.
94. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.
作者: John Deanfield.;A Michael Lincoff.;Steven E Kahn.;Scott S Emerson.;Ildiko Lingvay.;Benjamin M Scirica.;Jorge Plutzky.;Robert F Kushner.;Helen M Colhoun.;G Kees Hovingh.;Signe Stensen.;Peter E Weeke.;Ole Kleist Jeppesen.;Rafael Bravo.;Chau-Chung Wu.;Issei Komuro.;Ferruccio Santini.;Jøran Hjelmesæth.;Miguel Urina-Triana.;Silvio Buscemi.;Donna H Ryan.
来源: Lancet. 2025年406卷10516期2257-2268页
The SELECT trial found semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with cardiovascular disease but without diabetes. We report a prespecified analysis of the SELECT trial on the relationships between baseline adiposity measures, treatment-induced adiposity changes, and subsequent MACE risk.
95. Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial.
作者: J Randolph Hecht.;Young Suk Park.;Josep Tabernero.;Myung-Ah Lee.;Soohyeon Lee.;Anna C Virgili.;Marc Van den Eynde.;Elisa Fontana.;Marwan Fakih.;Gholamreza Asghari.;Jane So.;Alexander Stein.;Olivier Dubreuil.;Lubomir Bodnar.;Cixin Steven He.;Guan Wang.;Robina Smith.;Cathy Eng.;Anwaar Saeed.; .
来源: Lancet. 2025年406卷10517期2360-2370页
Zanzalintinib is a multitargeted tyrosine-kinase inhibitor that, when combined with atezolizumab, showed promising antitumour activity and manageable toxicity in a phase 1 study. We aimed to compare the efficacy and safety of zanzalintinib-atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.
96. Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.
作者: Zheng Wang.;Jia Fan.;Shaolai Zhou.;Yunfan Sun.;Fei Liang.;Yuan Ji.;Fangming Gu.;Tao Li.;Li Peng.;Tao Peng.;Xiaolun Huang.;Zhenbin Ding.;Dousheng Bai.;Bangde Xiang.;Guang Tan.;Tianfu Wen.;Yongyi Zeng.;Feng Han.;Yu Zhang.;Shengdong Wu.;Haitao Zhao.;Yi Chen.;Guoming Shi.;Zhiguo Hou.;Ying Sun.;Wenqing Zhu.;Jian Zhou.
来源: Lancet. 2025年406卷10515期2089-2099页
Surgical resection is the preferred curative approach for patients with early-stage hepatocellular carcinoma, but recurrence remains a major challenge. Consequently, neoadjuvant and adjuvant therapies have been proposed to reduce tumour burden and mitigate the risk of recurrence. The CARES-009 trial aimed to evaluate perioperative camrelizumab plus rivoceranib in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence.
97. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.
作者: Yunpeng Yang.;Huaqiang Zhou.;Linquan Tang.;Sufang Qiu.;Yaqian Han.;Dongmei Ji.;Xiaozhong Chen.;Feng Lei.;Song Qu.;Bin Deng.;Lusi Chen.;Jianli Huang.;Ye Guo.;Zhigang Liu.;Dongping Chen.;Jingao Li.;Xiaolei Shu.;Yan Qin.;Zhichao Fu.;Bihui Li.;Peng Zhang.;Shaoqing Chen.;Jinsheng Hong.;Yan Wei.;Xintian Qin.;Shenhong Qu.;Kunyu Yang.;Daren Lin.;Junxian Wang.;Lei Yang.;Sa Xiao.;Hai Zhu.;Yi Zhu.;Li Zhang.; .
来源: Lancet. 2025年406卷10516期2235-2243页
People with recurrent or metastatic nasopharyngeal carcinoma that progressed after chemotherapy and programmed cell death protein 1 (PD-1) and its ligand (PD-L1) inhibitors have few treatment options and a poor prognosis. We therefore aimed to investigate the efficacy and safety of the bispecific antibody-drug conjugate izalontamab brengitecan (iza-bren) in heavily pretreated individuals with recurrent or metastatic nasopharyngeal carcinoma.
98. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
作者: Zhiwei Chen.;Fang Yang.;Zhou Jiang.;Longhua Sun.;Lin Wu.;Zhengxiang Han.;Yun Fan.;Yanqiu Zhao.;Xingya Li.;Haipeng Xu.;Xiangjiao Meng.;Ying Liu.;Zhiye Zhang.;Hui Luo.;Xuelei Ma.;Xuezhen Ma.;Qin Shi.;Zhongmin Zhang.;Runxiang Yang.;Pingli Wang.;Pinhua Pan.;Xiaohong Ai.;Jie Li.;Xingxiang Pu.;Zhiwu Wang.;Jian Fang.;Ming He.;Yong He.;Shuliang Guo.;Juan Li.;Hongbiao Wang.;Junqiang Zhang.;Qian Chu.;Xuewen Liu.;Shenpeng Ying.;Hongcheng Wu.;Hongmei Sun.;Yinghua Ji.;Ming Zhou.;Chao Cao.;Kejing Tang.;Zhengguo Li.;Dairong Li.;Zhihong Zhang.;Jie Li.;Jianya Zhou.;Hongzhong Yang.;Yingying Du.;Hui Yang.;Jian Shi.;Hualin Chen.;Wenting Li.;Dongmei Lu.;Mingxiu Hu.;Zhongmin Maxwell Wang.;Baiyong Li.;Michelle Xia.;Shun Lu.
来源: Lancet. 2025年406卷10515期2078-2088页
Squamous non-small-cell lung cancer (NSCLC) is associated with worse clinical outcomes than non-squamous NSCLC, but treatment options are scarce. We aimed to evaluate the efficacy and safety of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as a first-line therapy for patients with advanced squamous NSCLC.
99. Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial.
作者: Charles Burdet.;Nadia Saïdani.;Céline Dupieux.;Adrien Lemaignen.;Etienne Canouï.;Laure Surgers.;Marc Olivier Vareil.;Agnès Lefort.;Raphaël Lepeule.;Nathan Peiffer-Smadja.;Alexandre Charmillon.;Vincent Le Moing.;David Boutoille.;Violaine Tolsma.;Sophie Abgrall.;Michel Wolff.;Pierre Tattevin.;Marina Esposito-Farèse.;François Vandenesch.;Xavier Duval.;Sarah Tubiana.;François-Xavier Lescure.; .
来源: Lancet. 2025年406卷10517期2349-2359页
Although widely used, cefazolin efficacy for the treatment of meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia has not thus far been investigated in a clinical trial. In this study, we aimed to compare the efficacy and safety of cefazolin with that of cloxacillin in patients with MSSA bacteraemia.
100. Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysis.
作者: Niklas Dyrby Johansen.;Daniel Modin.;Jacobo Pardo-Seco.;Carmen Rodriguez-Tenreiro-Sánchez.;Matthew M Loiacono.;Rebecca C Harris.;Marine Dufournet.;Robertus van Aalst.;Ayman Chit.;Carsten Schade Larsen.;Lykke Larsen.;Lothar Wiese.;Michael Dalager-Pedersen.;Brian L Claggett.;Kira Hyldekær Janstrup.;Carmen Duran-Parrondo.;Marta Piñeiro-Sotelo.;Martín Cribeiro-González.;Mónica Conde-Pájaro.;Susana Mirás-Carballal.;Juan-Manuel González-Pérez.;Scott D Solomon.;Pradeesh Sivapalan.;Cyril Jean-Marie Martel.;Jens Ulrik Stæhr Jensen.;Federico Martinón-Torres.;Tor Biering-Sørensen.; .; .
来源: Lancet. 2025年406卷10518期2425-2434页
Two large-scale trials comparing high-dose inactivated influenza vaccine (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) against hospitalisation outcomes have been conducted in Denmark and Spain. We aimed to analyse the pooled data from these trials to enhance generalisability and assess the relative vaccine effectiveness (rVE) of HD-IIV versus SD-IIV against severe clinical outcomes in older adults.
|